Javascript is not enabled in your web browser
This site uses javascript to enhance your browsing experience. Our vision tests require javascript and will not work properly if javascript is disabled. Please enable javascript in your web browser to access all features of this site.
Welcome to MyVisionTest.com, where patients with macular degeneration and other macular diseases can test their vision online. We offer our services free of charge. To use our test online you must first register here. Read the tutorial to learn more.
This site has been designed to be accessible by the visually impaired. Should you have any difficulties, please contact us.
Featured Articles
Select Article:
Outcomes following RPE transplantation for AMD
Despite the great success of anti-VEGF therapy for wet AMD, there remains a need for alternative treatments for those patients that do not respond to anti-VEGF therapy, or have dry AMD. Surgical treatments, such as maculoplasty, are continuing to evolve. This study finds that maculoplasty is able to maintain the vision of most patients with...
Full Article
Benefits of the treat-and-extend approach for AMD therapy
The argument in favor of using Avastin over Lucentis is almost always economic. Because Avastin is much cheaper than Lucentis, patients and their insurance provider can save lots of money by using Avastin. However, the "treat and extend" dosing strategy reveals another potential benefit of Avastin - its longer half-life. There are several studies...
Full Article
Lucentis for wet AMD with very low vision
There is some controversy regarding the benefit of anti-VEGF therapy for patients with very poor vision and/or long-standing maculopathy. It is thought that many of these patients may have scarring of the macula that could prevent them from responding favorably to treatment. A few small studies have been performed on this patient population with...
Full Article
Recent News

Jan 16, 2012
A phase 3 study of the efficacy of Eylea injections to treat neovascular AMD has shown sustained improvement in visual acuity at 96 weeks, Regeneron Pharmaceuticals and Bayer Healthcare announced in a press release. In the first year of the parallel VIEW 1 and VIEW 2 studies, patients received Eylea (aflibercept, Regeneron Pharmaceuticals)...
Full Article

Jan 16, 2012
Genentech and Regeneron Pharmaceuticals have agreed to a partial settlement with regard to ophthalmic sales of aflibercept injections in the United States, according to a press release. Under the plan, Regeneron will receive a non-exclusive license to certain patents for VEGF receptor proteins as well as to other technology patents, the release...
Full Article

Jan 16, 2012
Age-related Macular Degeneration (AMD) has long been thought to be more frequent in non-Hispanic whites than in blacks in the United States. This was based on observations reported in clinical case series. The use of new AMD classification schemes and severity scales in large population-based studies has confirmed that non-Hispanic whites have...
Full Article
About MyVisionTest
MyVisionTest.com has been developed to supplement the traditional Amsler Grid for those patients that have been instructed by their eye doctor to monitor their vision at home. MyVisionTest employs a technique known as entoptic perimetry to detect defects in your vision. Research has found entoptic perimetry to be superior to the traditional Amsler grid in detecting such defects. We also offer you the ability to save and review past test results, making it easier for you to detect changes in your vision over time.
Learn more
MyVisionTest Tutorial
If you are new to MyVisionTest, please take a moment to review our tutorial and try out the demo. The vision test requires that you have free multimedia software (Flash) installed and properly configured on your computer. If you are uncertain whether this software is currently installed on your computer, please take a moment to use our troubleshooter to test your system for compatibility with MyVisionTest.